# OnCo record senti-202 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/senti-202/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "senti-202" ;
  schema:name "SENTI-202"@en ;
  schema:description "SENTI-202 is an experimental off-the-shelf logic-gated CAR-NK cell therapy from Senti Biosciences, in phase 1 trials for acute myeloid leukaemia, myelodysplastic syndromes and CD33- or FLT3-expressing haematological malignancies."@en ;
  schema:url <https://onco.cc/drugs/senti-202/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sentibio.com/research-pipeline/senti-202/>, <https://www.sentibio.com/research-pipeline/senti-202/>, <https://www.sentibio.com/research-pipeline/pipeline/>, <https://clinicaltrials.gov/search?intr=SENTI-202> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Off-the-shelf logic-gated CAR-NK cell therapy (donor NK cells)" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/cd33/>, <https://onco.cc/targets/flt3/> ;
  onco:companies <https://onco.cc/companies/senti-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct06325748/> .